CN110229351A - 一种抗菌纤维素水凝胶的制备方法与应用 - Google Patents
一种抗菌纤维素水凝胶的制备方法与应用 Download PDFInfo
- Publication number
- CN110229351A CN110229351A CN201910530345.0A CN201910530345A CN110229351A CN 110229351 A CN110229351 A CN 110229351A CN 201910530345 A CN201910530345 A CN 201910530345A CN 110229351 A CN110229351 A CN 110229351A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- cellulose
- bacterial fibre
- solution
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 73
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 68
- 239000000835 fiber Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 86
- 229920002678 cellulose Polymers 0.000 claims abstract description 50
- 239000001913 cellulose Substances 0.000 claims abstract description 50
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 21
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 16
- 239000012895 dilution Substances 0.000 claims abstract description 15
- 238000010790 dilution Methods 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000004132 cross linking Methods 0.000 claims abstract description 11
- 239000011259 mixed solution Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 238000002507 cathodic stripping potentiometry Methods 0.000 claims abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 82
- 241000894006 Bacteria Species 0.000 claims description 45
- 229960003405 ciprofloxacin Drugs 0.000 claims description 41
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 25
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 24
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 24
- 239000001923 methylcellulose Substances 0.000 claims description 19
- 229920000609 methyl cellulose Polymers 0.000 claims description 16
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 241000305071 Enterobacterales Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 34
- 229910004298 SiO 2 Inorganic materials 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000004033 plastic Substances 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 31
- 239000001963 growth medium Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 230000009036 growth inhibition Effects 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 238000002798 spectrophotometry method Methods 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/08—Cellulose derivatives
- C08J2301/26—Cellulose ethers
- C08J2301/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2401/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2401/08—Cellulose derivatives
- C08J2401/26—Cellulose ethers
- C08J2401/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/34—Silicon-containing compounds
- C08K3/36—Silica
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种抗菌纤维素水凝胶的制备方法。首先配制抗菌剂溶液,将混合纤维素原料充分混合均匀,溶解于抗菌剂溶液中,制成纤维素溶液;在上述溶液中加入胶态二氧化硅CSPs稀释液,得到混合溶液;搅拌,于25~45℃下加热3~10min,经物理交联作用制成抗菌纤维素水凝胶。本发明抗菌纤维素水凝胶的制备工艺简单,纤维素衍生物通过动态和多价的选择性吸附作用连接至二氧化硅纳米颗粒上,同时加载抗菌剂药物,经物理交联作用即可成胶,适合于大规模工业生产。本发明制备的水凝胶能够应用于伤口辅料医疗卫生领域,对革兰氏阴性菌大肠杆菌和革兰氏阳性菌枯草芽孢杆菌具有抑菌作用。
Description
技术领域
本发明属于生物材料技术领域,具体涉及一种抗菌纤维素水凝胶的制备方法与应用。
背景技术
近年来,细菌等有害微生物在医疗领域中给人类带来极大的威胁。大量的抗生素被应用于治疗细菌感染性疾病,这导致了细菌对大部分抗生素药物产生了耐药性。目前延缓细菌耐药性主要有两种方法:一种是最大限度减少抗生素的使用,另一种是使用可以替代抗生素的新型抗菌剂。因此,开发新的抗菌材料已成为当前的研究热点。
根据制备水凝胶原料的来源不同,可以将其分为合成高分子水凝胶和天然高分子水凝胶。合成高分子水凝胶易于工业化生产合成、但存在难以降解、生物安全性低等缺点。天然高分子水凝胶具有可降解、生物安全性高、亲水性等特点,广泛应用于组织工程、生物材料和药物传递等领域。因此,选用天然高分子原料也成为一种趋势。
天然高分子纤维素水凝胶的生物安全性很高,对人体无毒副作用,适合用作与人体有亲密接触的医用材料,其为抗菌材料的开发提供了一个新的有用的起点。本发明将抗菌剂负载到凝胶网络中,它们一旦被水凝胶负载,可以在伤口附近局部使用,并且是减少用药剂量和抵抗耐药性的好方法。本发明制备的材料可广泛应用于生物医药领域,具有广阔的应用市场和极其高的产业附加值。
发明内容
发明目的:本发明目的在于提供一种抗菌纤维素水凝胶的制备方法。
技术方案:本发明的目的通过下述技术方案实现:
一种抗菌纤维素水凝胶的制备方法,包括以下步骤:
(1)配制浓度为200~1000μg/ml的抗菌剂溶液;
(2)将混合纤维素原料室温充分混合均匀后,溶解于所述抗菌剂溶液中,制成浓度2~4wt%的纤维素溶液;
(3)在步骤(2)的纤维素溶液中加入浓度为10~20wt%的胶态二氧化硅CSPs稀释液,得到混合溶液;此时抗菌剂在混合溶液中的浓度为100~500μg/ml;
(4)混合搅拌,于25~45℃下加热3~10min,经物理交联作用制成抗菌纤维素水凝胶。
本发明中,步骤(3)中的胶态二氧化硅CSPs稀释液的制备方法是:向浓度为50wt%的胶态二氧化硅CSPs(购自sigma公司)中加入蒸馏水,配制成浓度为10~20wt%胶态二氧化硅CSPs稀释液。
本发明的抗菌纤维素水凝胶的制备采取的是物理交联的方法,混合纤维素通过动态和多价的选择性吸附作用连接至二氧化硅纳米颗粒上,用这种方法制备的凝胶材料有很多优点,如不需添加交联剂,因此该水凝胶具有生物相容性更佳,低毒甚至无毒,同时易降解等优点。这类凝胶材料更适合用作与人体有亲密接触的医用材料或食品包装材料。本发明利用上述水凝胶作为载体,加载抗菌剂药物,制得的复合型水凝胶可以用于细菌性感染的局部治疗。
本发明中所述混合纤维素选自羟乙基纤维素HEC和甲基纤维素MC。
所述羟乙基纤维素和甲基纤维素的用量比为3:1~5:1。
所述抗菌剂选自环丙沙星。
本发明的抗菌纤维素水凝胶包含两种廉价而丰富的基本原料,一种是取自木屑、农作物秸秆等天然材料的羟乙基纤维素(HEC)和甲基纤维素(MC),另一种是取自沙子的胶态二氧化硅纳米粒子(CSPs)。这种简单廉价的工艺有望克服目前造价较高的限制,使以工业规模生产水凝胶成为可能。加上伸缩性强、无毒环保等特点,本发明的水凝胶材料有广泛应用前景。
本发明的另一个目的在于提供上述制备方法制备的抗菌纤维素水凝胶的应用,所述抗菌纤维素水凝胶应用于伤口辅料医疗卫生领域。
所述抗菌纤维素水凝胶在制备细菌性感染的局部治疗药物中的应用。
所述抗菌纤维素水凝胶对革兰氏阴性菌大肠杆菌和革兰氏阳性菌枯草芽孢杆菌的抑菌作用。
有益效果:
(1)本发明抗菌纤维素水凝胶的制备工艺简单,该水凝胶的制备采取的是物理交联的方法,纤维素衍生物通过动态和多价的选择性吸附作用连接至二氧化硅纳米颗粒上,同时加载抗菌剂药物,经物理交联作用即可成胶,适合于大规模工业生产。本发明将抗菌剂非共价地负载到凝胶网络中,用于其局部控制释放到组织,它们一旦被水凝胶负载,可以在伤口附近局部使用,是减少用药剂量和抵抗耐药性的好方法。
(2)本发明制备的水凝胶包含两种基本原料,一种是取自木屑、农作物秸秆等天然材料的羟乙基纤维素(HEC)和甲基纤维素(MC),另一种是取自沙子的胶态二氧化硅纳米粒子(CSPs)。这两种原料廉价而丰富,有望克服目前造价较高的限制,使以工业规模生产水凝胶成为可能。
(3)本发明中选取的原料对人体无毒副作用,适合用作与人体有亲密接触的医用材料,其为抗菌材料的开发提供了一个新的有用的起点。
(4)本发明中选取的抗菌剂环丙沙星作为一种新型广谱抗菌药,优点是毒性低、抗菌谱广,抑菌能力强而迅速。将环丙沙星负载在纤维素水凝胶中,能够针对性地应用于局部感染部位,有助于减少用药剂量,并延缓耐药性的出现,因此负载环丙沙星的纤维素水凝胶具有很大的临床应用潜力。
(5)本发明中将环丙沙星负载到纤维素水凝胶后,环丙沙星得到了缓释,从而延长了药物作用时间,也可以减少这类抗生素的使用。
(6)本发明中的水凝胶对革兰氏阴性菌大肠杆菌和革兰氏阳性菌枯草芽孢杆菌都具有良好的抑菌效果。从实际应用角度出发,该水凝胶可以应用于伤口辅料等医疗卫生领域。
附图说明
图1为抗菌纤维素水凝胶对大肠杆菌的抑制生长曲线;
图2为抗菌纤维素水凝胶对枯草芽孢杆菌的抑制生长曲线。
具体实施方式
下面通过具体实施例和附图对本发明技术方案进行详细说明,但是本发明的保护范围不局限于所述实施例。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。所用原料及试剂均为市售。
实施例1:
(1)称取0.2g环丙沙星,加蒸馏水至10ml,得到浓度为0.02g/ml的环丙沙星溶液,将其稀释100倍,最终得到浓度为200μg/ml的环丙沙星溶液。环丙沙星浓度为200μg/ml,浓度极低,接近水的密度,可以看做1ml环丙沙星溶液质量为1g。
(2)分别称取0.025g羟乙基纤维素HEC和0.005g甲基纤维素MC,羟乙基纤维素和甲基纤维素的用量比5:1。室温在EP管中充分混合均匀后,将其溶解于1ml浓度为200μg/ml的环丙沙星溶液中,制成浓度3wt%的纤维素溶液;
(3)取400mg浓度为50wt%的胶态二氧化硅CSPs(密度1.4g/ml,sigma公司),滴加蒸馏水至溶液总质量为2g,得到浓度为10wt%胶态二氧化硅CSPs稀释液;
(4)在步骤(2)的纤维素溶液中,滴加步骤(3)的胶态二氧化硅CSPs稀释液,得到混合溶液2ml;此时抗菌剂在混合溶液中的浓度为100μg/ml;
(5)混合搅拌,于37℃下加热8min,经物理交联作用制成抗菌纤维素水凝胶。
本实施例中,环丙沙星在抗菌纤维素水凝胶中的浓度为100μg/ml。
本发明经过上述制备过程形成抗菌纤维素水凝胶后,取样进行抗菌效果测试对比:
A对大肠杆菌的抗菌效果测试
将2%的大肠杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g抗菌纤维素水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的大肠杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图1所示。对照例中大肠杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例1的纤维素水凝胶在4h内OD600值逐渐增加,表明大肠杆菌处于增殖状态,但生长速率比对照例缓慢;4h后OD600值保持稳定,表明大肠杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
B对枯草芽孢杆菌的抗菌效果测试
将2%的枯草芽孢杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g抗菌纤维素水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的枯草芽孢杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图2所示。对照例中枯草芽孢杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例1中纤维素水凝胶5h内OD600值逐渐增加,表明枯草芽孢杆菌处于增殖状态,但生长速率比对照例缓慢;5h后OD600值保持稳定,表明枯草芽孢杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
实施例2:
(1)称取0.4g环丙沙星,加蒸馏水至10ml,得到浓度为0.04g/ml的环丙沙星溶液,将其稀释100倍,最终得到浓度为400μg/ml的环丙沙星溶液。环丙沙星浓度为400μg/ml,浓度极低,接近水的密度,可以看做1ml环丙沙星溶液质量为1g。
(2)分别称取0.015g羟乙基纤维素HEC和0.005g甲基纤维素MC,羟乙基纤维素和甲基纤维素的用量比3:1。室温在EP管中充分混合均匀后,将其溶解于1ml浓度为400μg/ml的环丙沙星溶液中,制成浓度2wt%的纤维素溶液;
(3)取480mg浓度为50wt%的胶态二氧化硅CSPs(密度1.4g/ml,sigma公司),滴加蒸馏水至溶液总质量为2g,得到浓度为12wt%胶态二氧化硅CSPs稀释液;
(4)在步骤(2)的纤维素溶液中,滴加步骤(3)的胶态二氧化硅稀释液,得到混合溶液2ml;此时抗菌剂在混合溶液中的浓度为200μg/ml;
(5)混合搅拌,于25℃下加热10min,经物理交联作用制成抗菌纤维素水凝胶。
本实施例中环丙沙星在抗菌纤维素水凝胶中的浓度为200μg/ml。
本发明经过上述制备过程形成抗菌纤维素水凝胶后,取样进行抗菌效果测试对比:
A对大肠杆菌的抗菌效果测试
将2%的大肠杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的大肠杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图1所示。对照例中大肠杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例2纤维素水凝胶在4h内OD600值逐渐增加,表明大肠杆菌处于增殖状态,但生长速率比对照例缓慢;4h后OD600值保持稳定,表明大肠杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
B对枯草芽孢杆菌的抗菌效果测试
将2%的枯草芽孢杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的枯草芽孢杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图2所示。对照例中枯草芽孢杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例2中纤维素水凝胶5h内OD600值逐渐增加,表明枯草芽孢杆菌处于增殖状态,但生长速率比对照例缓慢;5h后OD600值保持稳定,表明枯草芽孢杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
实施例3:
(1)称取0.5g环丙沙星,加蒸馏水至10ml,得到浓度为0.05g/ml的环丙沙星溶液,将其稀释100倍,最终得到浓度为500μg/ml的环丙沙星溶液。环丙沙星浓度为500μg/ml,浓度极低,接近水的密度,可以看做1ml环丙沙星溶液质量为1g。
(2)分别称取0.02g羟乙基纤维素HEC和0.005g甲基纤维素MC,羟乙基纤维素和甲基纤维素的用量比4:1。室温在EP管中充分混合均匀后,将其溶解于1ml浓度为500μg/ml的环丙沙星溶液中,制成浓度2.5wt%的纤维素溶液;
(3)取800mg浓度为50wt%的胶态二氧化硅CSPs(密度1.4g/ml,sigma公司),滴加蒸馏水至溶液总质量为2g,得到浓度为20wt%胶态二氧化硅CSPs稀释液;
(4)在步骤(2)的纤维素溶液中,滴加步骤(3)的胶态二氧化硅稀释液,得到混合溶液2ml;此时抗菌剂在混合溶液中的浓度为250μg/ml;
(5)混合搅拌,于30℃下加热6min,经物理交联作用制成抗菌纤维素水凝胶。
本实施例中环丙沙星在抗菌纤维素水凝胶中的浓度为250μg/ml;
本发明经过上述制备过程形成抗菌纤维素水凝胶后,取样进行抗菌效果测试对比:
A对大肠杆菌的抗菌效果测试
将2%的大肠杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的大肠杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图1所示。对照例中大肠杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例3纤维素水凝胶在4h内OD600值逐渐增加,表明大肠杆菌处于增殖状态,但生长速率比对照例缓慢;4h后OD600值保持稳定,表明大肠杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
B对枯草芽孢杆菌的抗菌效果测试
将2%的枯草芽孢杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的枯草芽孢杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图2所示。对照例中枯草芽孢杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例3中纤维素水凝胶5h内OD600值逐渐增加,表明枯草芽孢杆菌处于增殖状态,但生长速率比对照例缓慢;5h后OD600值保持稳定,表明枯草芽孢杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
实施例4:
(1)称取1g环丙沙星,加蒸馏水至10ml,得到浓度为0.1g/ml的环丙沙星溶液,将其稀释100倍,最终得到浓度为1000μg/ml的环丙沙星溶液。环丙沙星浓度为1000μg/ml,浓度极低,接近水的密度,可以看做1ml环丙沙星溶液质量为1g。
(2)分别称取0.03g羟乙基纤维素HEC和0.01g甲基纤维素MC,羟乙基纤维素和甲基纤维素的用量比3:1。室温在EP管中充分混合均匀后,将其溶解于1ml浓度为1000μg/ml的环丙沙星溶液中,制成浓度4wt%的纤维素溶液;
(3)取600mg浓度为50wt%的胶态二氧化硅CSPs(密度1.4g/ml,sigma公司),滴加蒸馏水至溶液总质量为2g,得到浓度为15wt%胶态二氧化硅CSPs稀释液;
(4)在步骤(2)的纤维素溶液中,滴加步骤(3)的胶态二氧化硅稀释液,得到混合溶液2ml;此时抗菌剂在混合溶液中的浓度为500μg/ml;
(5)混合搅拌,于42℃下加热4min,经物理交联作用制成抗菌纤维素水凝胶。
本实施例中环丙沙星在抗菌纤维素水凝胶中的浓度为500μg/ml。
本发明经过上述制备过程形成抗菌纤维素水凝胶后,取样进行抗菌效果测试对比:
A对大肠杆菌的抗菌效果测试
将2%的大肠杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的大肠杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图1所示。对照例中大肠杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例4纤维素水凝胶在4h内OD600值逐渐增加,表明大肠杆菌处于增殖状态,但生长速率比对照例缓慢;4h后OD600值保持稳定,表明大肠杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
B对枯草芽孢杆菌的抗菌效果测试
将2%的枯草芽孢杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的枯草芽孢杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图2所示。对照例中枯草芽孢杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例4中纤维素水凝胶5h内OD600值逐渐增加,表明枯草芽孢杆菌处于增殖状态,但生长速率比对照例缓慢;5h后OD600值保持稳定,表明枯草芽孢杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
实施例5:
(1)称取0.8g环丙沙星,加蒸馏水至10ml,得到浓度为0.08g/ml的环丙沙星溶液,将其稀释100倍,最终得到浓度为800μg/ml的环丙沙星溶液。环丙沙星浓度为800μg/ml,浓度极低,接近水的密度,可以看做1ml环丙沙星溶液质量为1g。
(2)分别称取0.032g羟乙基纤维素HEC和0.008g甲基纤维素MC,羟乙基纤维素和甲基纤维素的用量比4:1。室温在EP管中充分混合均匀后,将其溶解于1ml浓度为800μg/ml的环丙沙星溶液中,制成浓度4wt%的纤维素溶液;
(3)取680mg浓度为50wt%的胶态二氧化硅CSPs(密度1.4g/ml,sigma公司),滴加蒸馏水至溶液总质量为2g,得到浓度为17wt%胶态二氧化硅CSPs稀释液;
(4)在步骤(2)的纤维素溶液中,滴加步骤(3)的胶态二氧化硅稀释液,得到混合溶液2ml;此时抗菌剂在混合溶液中的浓度为400μg/ml;
(5)混合搅拌,于45℃下加热3min,经物理交联作用制成抗菌纤维素水凝胶。
本实施例中环丙沙星在抗菌纤维素水凝胶中的浓度为400μg/ml。
本发明经过上述制备过程形成抗菌纤维素水凝胶后,取样进行抗菌效果测试对比:
A对大肠杆菌的抗菌效果测试
将2%的大肠杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的大肠杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图1所示。对照例中大肠杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例5纤维素水凝胶在3h内OD600值逐渐增加,表明大肠杆菌处于增殖状态,但生长速率比对照例缓慢;3h后OD600值保持稳定,表明大肠杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
B对枯草芽孢杆菌的抗菌效果测试
将2%的枯草芽孢杆菌接种到装有40mlLB液体培养基的锥形瓶中。将0.1g水凝胶加入接种后的LB培养基中,对照例为自然状态下生长的枯草芽孢杆菌。每个锥形瓶中取1ml菌液,用分光光度计测菌液的初始OD600。将对照例和不同处理组的培养基置于摇床中37℃、160rpm培养8h。每隔1小时取1ml菌液,测定菌液的OD600,并绘制生长抑制曲线,如图2所示。对照例中枯草芽孢杆菌处于自然状态,其逐渐生长,OD600值随着时间增加而升高。本发明实施例5中纤维素水凝胶4h内OD600值逐渐增加,表明枯草芽孢杆菌处于增殖状态,但生长速率比对照例缓慢;4h后OD600值保持稳定,表明枯草芽孢杆菌停止生长,本发明纤维素水凝胶实施例抗菌效果实现。
由此可见,本发明的抗菌纤维素水凝胶对革兰氏阴性菌大肠杆菌和革兰氏阳性菌枯草芽孢杆菌有良好的抑菌效果,所述抗菌纤维素水凝胶能够应用在制备细菌性感染的局部治疗药物方面,可以应用于伤口辅料等医疗卫生领域。
如上所述,尽管参照特定的优选实施例已经表示和表述了本发明,但其不得解释为对本发明自身的限制。在不脱离所附权利要求定义的本发明的精神和范围前提下,可对其在形式上和细节上作出各种变化。
Claims (7)
1.一种抗菌纤维素水凝胶的制备方法,其特征在于,包括以下步骤:
(1)配制浓度为200~1000μg/ml的抗菌剂溶液;
(2)将混合纤维素原料室温充分混合均匀后,溶解于所述抗菌剂溶液中,制成浓度2~4wt%的纤维素溶液;
(3)在步骤(2)的纤维素溶液中加入浓度为10~20wt%的胶态二氧化硅CSPs稀释液,得到混合溶液;此时抗菌剂在混合溶液中的浓度为100~500μg/ml;
(4)混合搅拌,于25~45℃下加热3~10min,经物理交联作用制成抗菌纤维素水凝胶。
2.根据权利要求1所述的制备方法,其特征在于,所述混合纤维素选自羟乙基纤维素HEC和甲基纤维素MC。
3.根据权利要求2所述的制备方法,其特征在于,所述羟乙基纤维素和甲基纤维素的用量比为3:1~5:1。
4.根据权利要求1所述的制备方法,其特征在于,所述抗菌剂选自环丙沙星。
5.权利要求1~4任一项所述的制备方法制备的抗菌纤维素水凝胶的应用,其特征在于,所述抗菌纤维素水凝胶应用于伤口辅料医疗卫生领域。
6.根据权利要求5所述的应用,其特征在于,所述抗菌纤维素水凝胶在制备细菌性感染的局部治疗药物中的应用。
7.根据权利要求6所述的应用,其特征在于,所述抗菌纤维素水凝胶对革兰氏阴性菌大肠杆菌和革兰氏阳性菌枯草芽孢杆菌的抑菌作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530345.0A CN110229351A (zh) | 2019-06-19 | 2019-06-19 | 一种抗菌纤维素水凝胶的制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910530345.0A CN110229351A (zh) | 2019-06-19 | 2019-06-19 | 一种抗菌纤维素水凝胶的制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110229351A true CN110229351A (zh) | 2019-09-13 |
Family
ID=67856208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910530345.0A Pending CN110229351A (zh) | 2019-06-19 | 2019-06-19 | 一种抗菌纤维素水凝胶的制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110229351A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113101280A (zh) * | 2021-04-09 | 2021-07-13 | 哈尔滨理工大学 | 一种固体脂质纳米细菌纤维素眼保健贴及其制备方法和应用 |
CN113845691A (zh) * | 2021-09-28 | 2021-12-28 | 江苏省农业科学院 | 一种二维或三维纤维素基多孔抗菌材料及其制备方法 |
CN115843790A (zh) * | 2022-12-04 | 2023-03-28 | 吉林大学 | 一种负载紫苏酸的抗菌水凝胶的制备及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070264315A1 (en) * | 2006-05-10 | 2007-11-15 | Produits Dentaires Pierre Rolland | Paste usable as a dressing on the oral mucosae or the skin |
CN102178973A (zh) * | 2010-01-15 | 2011-09-14 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备、和应用 |
CN102352058A (zh) * | 2011-08-04 | 2012-02-15 | 华南农业大学 | 稳定水溶性纤维素水凝胶粘度的复合添加剂及应用 |
CN107260693A (zh) * | 2016-10-12 | 2017-10-20 | 钟术光 | 延缓药物释放的组合物 |
CN109316623A (zh) * | 2018-09-19 | 2019-02-12 | 华熙福瑞达生物医药有限公司 | 一种包覆有活性分子的双层多孔生物可降解材料及其制备方法和应用 |
CN109700601A (zh) * | 2019-02-02 | 2019-05-03 | 天津嘉氏堂科技有限公司 | 一种水胶体硅敷料贴 |
CN109731121A (zh) * | 2018-12-31 | 2019-05-10 | 武汉工程大学 | 一种含有介孔二氧化硅的纤维素和壳聚糖复合敷料的制备方法 |
-
2019
- 2019-06-19 CN CN201910530345.0A patent/CN110229351A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070264315A1 (en) * | 2006-05-10 | 2007-11-15 | Produits Dentaires Pierre Rolland | Paste usable as a dressing on the oral mucosae or the skin |
CN102178973A (zh) * | 2010-01-15 | 2011-09-14 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备、和应用 |
CN102352058A (zh) * | 2011-08-04 | 2012-02-15 | 华南农业大学 | 稳定水溶性纤维素水凝胶粘度的复合添加剂及应用 |
CN107260693A (zh) * | 2016-10-12 | 2017-10-20 | 钟术光 | 延缓药物释放的组合物 |
CN109316623A (zh) * | 2018-09-19 | 2019-02-12 | 华熙福瑞达生物医药有限公司 | 一种包覆有活性分子的双层多孔生物可降解材料及其制备方法和应用 |
CN109731121A (zh) * | 2018-12-31 | 2019-05-10 | 武汉工程大学 | 一种含有介孔二氧化硅的纤维素和壳聚糖复合敷料的制备方法 |
CN109700601A (zh) * | 2019-02-02 | 2019-05-03 | 天津嘉氏堂科技有限公司 | 一种水胶体硅敷料贴 |
Non-Patent Citations (2)
Title |
---|
TIAN GONG ET AL.: "Gelation of hydroxyethyl cellulose aqueous solution induced by addition of colloidal silica nanoparticles", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
沈建忠 等: "《兽药手册 第7版》", 31 July 2016, 中国农业大学出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113101280A (zh) * | 2021-04-09 | 2021-07-13 | 哈尔滨理工大学 | 一种固体脂质纳米细菌纤维素眼保健贴及其制备方法和应用 |
CN113101280B (zh) * | 2021-04-09 | 2021-09-21 | 哈尔滨理工大学 | 一种固体脂质纳米细菌纤维素眼保健贴及其制备方法和应用 |
CN113845691A (zh) * | 2021-09-28 | 2021-12-28 | 江苏省农业科学院 | 一种二维或三维纤维素基多孔抗菌材料及其制备方法 |
CN113845691B (zh) * | 2021-09-28 | 2024-03-22 | 江苏省农业科学院 | 一种二维或三维纤维素基多孔抗菌材料及其制备方法 |
CN115843790A (zh) * | 2022-12-04 | 2023-03-28 | 吉林大学 | 一种负载紫苏酸的抗菌水凝胶的制备及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912634B (zh) | 一种含纳米银/纳米二氧化硅的抗菌生物敷料的制备方法 | |
CN110229351A (zh) | 一种抗菌纤维素水凝胶的制备方法与应用 | |
CN101927029B (zh) | 一种含纳米银的壳聚糖/聚乙烯醇海绵敷料的制备方法 | |
Lambe et al. | Foreign-body-associated experimental osteomyelitis induced with Bacteroides fragilis and Staphylococcus epidermidis in rabbits. | |
JP2016525998A (ja) | ドープ化金属酸化物ナノ粒子及びその使用 | |
CN107130431A (zh) | 一种新型光动力抗菌面料的制备方法及其应用 | |
CN103860547B (zh) | 一种中草药组合物抗菌纳米乳及其制备方法 | |
KR102414533B1 (ko) | 이식 가능한 페이스트 및 이의 용도 | |
CN107254742A (zh) | 用于医用敷料的含纳米银聚乙烯醇/丝胶复合纤维网 | |
CN105796370B (zh) | 用于根管消毒的溶致液晶前体及其制备方法和应用 | |
Boggione et al. | Preparation of polyvinyl alcohol hydrogel containing bacteriophage and its evaluation for potential use in the healing of skin wounds | |
CN104758976A (zh) | 负载了温敏性微粒蛋白类药物的双网络水凝胶及制备方法 | |
CN104784103B (zh) | 基于寡聚氨基酸两亲分子可注射抗菌水凝胶 | |
JP6468559B2 (ja) | 動物用の口腔用組成物並びにそれを使用した動物用の歯周病予防剤及び動物用の口臭予防剤 | |
CN102450973A (zh) | 一种含有柑橘精华的多功能湿巾 | |
CN107998401B (zh) | 一种具有缓释效果的口腔药物制剂及其制备方法 | |
Khardori et al. | Effect of subinhibitory concentrations of clindamycin and trospectomycin on the adherence of Staphylococcus epidermidis in an in vitro model of vascular catheter colonization | |
KR101934878B1 (ko) | 천연광물을 함유하는 피부미용 조성물 및 이를 이용한 미용팩 제조방법 | |
CN115350197A (zh) | 泽泻醇A-24-醋酸酯在提高MRSA对β-内酰胺类抗生素敏感性方面的应用 | |
Owusu-Ababio et al. | Effectiveness of ciprofloxacin microspheres in eradicating bacterial biofilm | |
CN101161728B (zh) | 具有抑菌功效的明胶-Ag纳米复合物及其制备方法 | |
Yao et al. | Smart chimeric lysin clyc loaded alginate hydrogel reduces staphylococcus aureus induced bone infection | |
Wu | Talking about the new uses of several inorganic antibacterial materials | |
CN111514181A (zh) | 抗菌组合物、抗菌复合纳米颗粒及其制备方法、靶向缓释纳米私密凝胶 | |
CN114958676B (zh) | 一种基于芽孢杆菌发酵产物的抗菌剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |